SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

New research has revealed the role of two membrane proteins in the spread of misfolded α-synuclein from neuron to neuron.

Studies have uncovered that abnormalities in the alpha-synuclein protein are likely a causal factor for numerous diseases, including Parkinson’s disease, multiple system atrophy (MSA), dementia with ...

Amsterdam, NL, November 13, 2019 - Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease (PD). Investigators are testing the ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with ...

Novartis is returning to the alpha-synuclein protein as a possible treatment for Parkinson’s disease, signing a licensing deal worth up to $2.2bn for Arrowhead Pharmaceuticals’ preclinical candidate.

Alpha synuclein is a key drug target in Parkinson's Disease with the ability to aggregate into oligomers and fibrils. Research into α-synuclein has rapidly progressed in recent years with a lot of the ...

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...

Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by the aggregation of alpha-synuclein in the brain. Now, scientists have developed a radioligand that facilitates the ...

Gain Therapeutics (GANX) provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson’s ...